New Jersey has long been called America's medicine chest. It hosts the US headquarters and major sites of many of the world's largest pharmaceutical companies, a dense layer of generics manufacturers — including the US operations of many Indian generics companies — plus CDMOs, CROs and suppliers along the corridor into Pennsylvania.
Validation here looks different from a young biotech hub. The typical challenge is not building a first validated system; it is maintaining a very large, ageing validated estate, often inherited through acquisitions, under steady inspection pressure. This guide covers those challenges and how teams are modernising. For the core discipline see computer system validation.
The legacy estate problem
Large established manufacturers can run hundreds of validated systems, some in place for decades. Many were validated under older, document-heavy approaches and have been patched and extended since. The result is validation debt: systems that are technically validated but where the package no longer matches the system as it runs today.
- Periodic review backlogs — reviews overdue or done as box-ticking, which inspectors spot quickly.
- Unsupported platforms — operating systems and databases past end of support that are still running GxP work.
- Undocumented changes — small configuration changes made over years that never went through change control.
- Knowledge loss — the people who understood why a system was configured a certain way have moved on.
The first step is an honest inventory: which systems are GxP-relevant, what their real validation status is, and which carry the most risk. A structured GxP risk assessment turns that inventory into a priority list.
Validation after an acquisition
Mergers and acquisitions are constant in this market, and every deal brings a second set of systems, SOPs and validation standards. The acquiring company inherits the target's compliance history — including any open findings — from day one.
- Do a compliance due diligence, not just an IT one. Look at recent inspection outcomes, open CAPAs and the real state of periodic reviews before integration planning starts.
- Decide early which standard wins. Running two validation methodologies in parallel for years is expensive and confusing.
- Treat system consolidation as a validated change. Migrating data from an acquired system is a GxP activity: plan it, verify it and keep the records readable.
Generics and inspection pressure
Generics manufacturers compete on cost and speed, and that pressure shows in inspections. The themes are consistent: laboratory data integrity, audit trail review, investigations of out-of-specification results, and control of spreadsheets used for calculations. Many of these companies also run sites in India, so the same themes appear on both sides — see GxP compliance in India.
The companies that do best treat one quality standard as global, rather than letting practice vary by site. See data integrity services and preparing for a GxP audit.
Modernising without starting over
Move to risk-based assurance. The FDA's Computer Software Assurance guidance supports focusing effort where risk is highest instead of producing the same exhaustive package for every system. For a large estate this is the single biggest lever on cost. See CSA services.
Clear the periodic review backlog by risk. Review high-risk systems first, and use the review to find the systems that should be retired rather than maintained.
Retire what you can. Every system decommissioned properly — with its data archived in readable form — is one fewer periodic review, access review and supplier relationship forever.
Automate the documentation load. With hundreds of systems, document effort is the constraint. Teams are turning to GxP software and GxP AI to draft and trace validation documents for human review, keeping the approval with a qualified person while the volume of routine drafting goes down.
Where to go next
Explore GxP Copilot for AI-native validation, TraceDraft for source-traceable clinical documentation, or book a demo to see either on your own data.